78 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
. 65 (89%) patients had cytokine release syndrome (CRS), with the majority of CRS cases at grades 1 and 2, and 9 (12%) at grade 3 and no cases reported … at Grade 4 or 5. 64 (88%) patients had hematopoietic cytopenias and the majority (86%) of events were Grade 3 or higher. Less than 5% of patients
8-K
EX-10.2
wpegs78 p5n
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
o7nv v1k9e
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
424B3
713 twx5drfghlki
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
texumo7j
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
yijc56p mekvn
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-99.1
nlg1l
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am
8-K
EX-99.1
bqe12jzzd
12 Nov 21
Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS
6:30am
8-K
EX-99.1
nbwtpxfyn
13 Sep 21
Other Events
7:08am